Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 9;8(3):rkae082.
doi: 10.1093/rap/rkae082. eCollection 2024.

Paradoxical psoriasis with IL-17 inhibitors

Shikha Singla  1 , Dimitri Luz  2
Affiliations

Paradoxical psoriasis with IL-17 inhibitors

Shikha Singla et al. Rheumatol Adv Pract. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study design
See this image and copyright information in PMC

References

    1. Singh JA, Wells GA, Christensen R. et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;2011:CD008794. - PMC - PubMed
    1. Pugliese D, Guidi L, Ferraro PM. et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther 2015;42:880–8. - PubMed
    1. Davydova A, Kurochkina Y, Goncharova V, Vorobyeva M, Korolev M.. The interleukine-17 cytokine family: role in development and progression of spondyloarthritis, current and potential therapeutic inhibitors. Biomedicines 2023;11:1328. - PMC - PubMed
    1. Karamanakos A, Vergou T, Panopoulos S. et al. Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy. Eur J Dermatol 2021;31:307–17. - PubMed
    1. Ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S.. The TNF/IL-23/IL-17 axis-head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol 2020;92:e12946. - PubMed

LinkOut - more resources